Get the Stockscreener App
6.75
1.32%
-0.07
Silexion Therapeutics Corp stock is traded at $6.75, with a volume of 27,083.
It is down -1.32% in the last 24 hours and down -45.60% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$6.82
Open:
$6.9
24h Volume:
27,083
Relative Volume:
0.32
Market Cap:
$4.94M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.2895
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
-8.56%
1M Performance:
-45.60%
6M Performance:
-46.90%
1Y Performance:
-97.28%
1-Day Range:
$6.51
$6.90
1-Week Range:
$6.51
$7.48
52-Week Range:
$6.51
$256.50
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
6.75 | 5.47M | 0 | -16.42M | -6.75M | -23.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.06 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.03 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
466.80 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
662.25 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Is There Enough Volume to Lift Silexion Therapeutics Corp Equity WarrantWeekly Market Report & AI Based Buy/Sell Signal Reports - beatles.ru
Silexion Therapeutics Executes Reverse Stock Split - TipRanks
Silexion Therapeutics Increases Authorized Share Capital - MSN
Silexion Therapeutics shareholders approve increase in authorized share capital By Investing.com - Investing.com Canada
Silexion Therapeutics Corp Reversal Rally May Surprise BearsJuly 2025 PreEarnings & AI Based Trade Execution Alerts - thegnnews.com
Silexion Therapeutics shareholders approve increase in authorized share capital - Investing.com
Is This a Bottoming Phase for Silexion Therapeutics CorpJuly 2025 Highlights & Community Verified Swing Trade Signals - newsimpact.co.kr
Is Silexion Therapeutics Corp Equity Warrant stock reversal real or fakeJuly 2025 Reactions & Real-Time Stock Movement Alerts - Newser
Advanced analytics toolkit walkthrough for Silexion Therapeutics Corp2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - Newser
Should you hold or exit Silexion Therapeutics Corp Equity Warrant nowEarnings Trend Report & High Conviction Investment Ideas - Newser
What to do if you’re stuck in Silexion Therapeutics CorpFed Meeting & Low Drawdown Trading Strategies - Newser
What high frequency data says about Silexion Therapeutics CorpJuly 2025 Short Interest & Weekly Breakout Watchlists - Newser
Silexion Therapeutics Corp Equity Warrant stock trendline breakdown2025 EndofYear Setup & Risk Adjusted Swing Trade Ideas - Newser
Using flow based indicators on Silexion Therapeutics Corp Equity WarrantWeekly Stock Analysis & Safe Capital Investment Plans - Newser
Is Silexion Therapeutics Corp still worth holding after the dipQuarterly Trade Summary & Real-Time Sentiment Analysis - Newser
Silexion Therapeutics Corp Company’s Quarterly Earnings Growth: What the Numbers SayGap Down & Weekly Top Performers Watchlists - Newser
Published on: 2025-08-17 04:35:28 - Newser
Will Silexion Therapeutics Corp bounce back from current supportPortfolio Update Summary & Safe Capital Investment Plans - Newser
Is Silexion Therapeutics Corp Equity Warrant in Accumulation Phase Now2025 Technical Patterns & Daily Profit Maximizing Tips - newsyoung.net
Does Silexion Therapeutics Corp qualify in momentum factor screeningJuly 2025 Selloffs & Technical Entry and Exit Alerts - Newser
Is Silexion Therapeutics Corp Equity Warrant stock good for income investorsJuly 2025 Review & Daily Oversold Stock Bounce Ideas - thegnnews.com
Is Silexion Therapeutics Corp stock ready for a breakoutMarket Risk Analysis & Fast Moving Trade Plans - Newser
Chart overlay techniques for tracking Silexion Therapeutics Corp2025 Price Targets & Reliable Breakout Stock Forecasts - Newser
How to interpret RSI for Silexion Therapeutics Corp Equity Warrant stockDay Trade & AI Enhanced Execution Alerts - Newser
Exit strategy if you’re trapped in Silexion Therapeutics CorpTrade Risk Summary & Short-Term High Return Ideas - Newser
Risk adjusted return profile for Silexion Therapeutics Corp analyzedWeekly Stock Analysis & AI Driven Stock Movement Reports - Newser
What is Silexion Therapeutics Corp’s market positionWeekly Stock Analysis & Entry Point Confirmation Alerts - 선데이타임즈
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - ADVFN Brasil
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN Brasil
Order Book Volume Tilts Bullish on Silexion Therapeutics Corp2025 AllTime Highs & High Yield Equity Trading Tips - newsimpact.co.kr
How sensitive is Silexion Therapeutics Corp Equity Warrant to inflationEarnings Miss & Weekly Chart Analysis and Trade Guides - sundaytimes.kr
How Silexion Therapeutics Corp stock performs during market volatilityMarket Weekly Review & Fast Moving Market Watchlists - Newser
Form 424B3 Silexion Therapeutics - StreetInsider
Silexion Therapeutics reports Q2 EPS ($4.32) vs. ($197.80) last year - TipRanks
Breakthrough: Silexion's Cancer Drug Shows 97% Efficacy Across Multiple Tumor Types, Phase 2/3 Trials Coming - Stock Titan
What are Silexion Therapeutics Corp company’s key revenue driversInvest confidently with professional guidance - Jammu Links News
What is Silexion Therapeutics Corp company’s growth strategyGet insider insights into market trends - Jammu Links News
What is the dividend policy of Silexion Therapeutics Corp Equity Warrant stockBuild wealth faster with consistent investment plans - Jammu Links News
How strong is Silexion Therapeutics Corp Equity Warrant company’s balance sheetMaximize portfolio value with expert tips - Jammu Links News
What are Silexion Therapeutics Corp Equity Warrant company’s key revenue driversAchieve breakthrough investment performance - Jammu Links News
How does Silexion Therapeutics Corp generate profit in a changing economyMaximize returns with strategic trading plans - Jammu Links News
How does Silexion Therapeutics Corp Equity Warrant compare to its industry peersRobust investment performance - Jammu Links News
Is Silexion Therapeutics Corp a growth stock or a value stockOutstanding risk-reward balance - Jammu Links News
Should I hold or sell Silexion Therapeutics Corp stock in 2025Free Daily Trading Room Entry - Jammu Links News
What makes Silexion Therapeutics Corp stock price move sharplyAchieve rapid growth with smart investments - Jammu Links News
What are the latest earnings results for Silexion Therapeutics CorpMaster the art of timing market moves - Jammu Links News
Is Silexion Therapeutics Corp Equity Warrant stock overvalued or undervaluedDouble-digit growth - Jammu Links News
Silexion Therapeutics Corp Stock Analysis and ForecastMarket-crushing stock picks - Jammu Links News
What is Silexion Therapeutics Corp Equity Warrant company’s growth strategyExponential wealth increase - Jammu Links News
When is Silexion Therapeutics Corp Equity Warrant stock expected to show significant growthUnlock powerful insights from market experts - Jammu Links News
Should I hold or sell Silexion Therapeutics Corp Equity Warrant stock in 2025Unlock powerful trading techniques - Jammu Links News
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):